Brookfield, CT, United States of America

Sokol Haxhinasto

This inventor holds 8 USPTO granted patents and 6 published patent applications and 3 EPO patents. Top assignees: Regeneron Pharmaceuticals, Inc., Regeneran Pharmaceuticals, Inc.. Active years: 2022-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sokol Haxhinasto. Retrieved from https://idiyas.com/inventor/sokol-haxhinasto

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8 (Patent Applications = 6)

% Patents Active = 100.0

EPO Patents = 3 (Patent Applications = 9)

Average Co-Inventor Count = 5.2

ph-index = 1

Forward Citations = 1(Granted Patents)

Company Filing History:

7 out of 1,482

Regeneron Pharmaceuticals, Inc.

patents

1 out of 49

Regeneran Pharmaceuticals, Inc.

patents

Years Active: 2022-2025

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12497460 - ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF (2025-12-16),

2. 12471579 - MOUSE MODEL OF DITRA DISEASE AND USES THEREOF (2025-11-18),

3. 12209180 - Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as LXR agonists (2025-01-28),

4. 12060428 - Anti-IL36R antibodies (2024-08-13),

5. 11825819 - loss of function rodent model (2023-11-28),

6. 11589562 - Mouse model of DITRA disease and uses thereof (2023-02-28),

7. 11377502 - Anti-MSR1 antibodies and methods of use thereof (2022-07-05),

8. 11267893 - Anti-IL36R antibodies (2022-03-08),

Title: Sokol Haxhinasto: Innovator in Pharmaceutical Sciences

Introduction

Sokol Haxhinasto is a prominent inventor based in Brookfield, CT (US), known for his significant contributions to pharmaceutical sciences. He holds a total of six patents, showcasing his innovative approach to addressing complex medical challenges. His work primarily focuses on developing novel compounds and therapeutic methods.

Latest Patents

Among his latest patents, Haxhinasto has developed bis-octahydrophenanthrene carboxamide derivatives and protein conjugates for use as liver X receptor (LXR) agonists. These compounds are designed to treat diseases associated with the LXR, providing new avenues for therapeutic intervention. Additionally, he has created anti-IL36R antibodies, which specifically bind to the human Interleukin-36 receptor (IL36R). This invention offers methods for treating inflammatory conditions such as palmo-plantar pustular psoriasis and ulcerative colitis, highlighting his commitment to advancing medical treatments.

Career Highlights

Haxhinasto has worked with notable companies in the pharmaceutical industry, including Regeneron Pharmaceuticals, Inc. His experience in these organizations has allowed him to refine his skills and contribute to groundbreaking research and development in the field.

Collaborations

Throughout his career, Haxhinasto has collaborated with esteemed colleagues such as William C Olson and Andrew J Murphy. These partnerships have fostered a collaborative environment that enhances innovation and drives progress in pharmaceutical research.

Conclusion

Sokol Haxhinasto's work exemplifies the spirit of innovation in the pharmaceutical industry. His patents and collaborations reflect a dedication to improving healthcare through scientific advancements. His contributions continue to pave the way for future developments in medical treatments.

Profile summary based on public USPTO records.